近日，昆药集团在互动平台向投资者表示，和上美集团的合作，公司既是合作产品核心原料的供应商， 也是合作产品渠道的共建者。安敏优系列的核心成分青蒿油AN+由昆药研发、生产和提供，公司希望 通过与国内头部化妆品企业的跨界合作，将天然植物成分与现代科技有效融合，助推青蒿产业链发展。 该合作通过资源共享与优势互补，有望为公司带来包括投资收益、品牌赋能等多方面的积极效应，进一 步拓展公司在大健康板块的业务边界与盈利能力。 据悉，安敏优青蒿护肤系列功效护肤产品是昆药集团敏感肌微生态的护肤品牌，该品牌于2022年首发上 市。2020年，昆药集团便与上海上美公司开展合作。2025年上半年，昆药集团实现营收33.51亿元，同 比下降11.68%；实现归母净利润1.98亿元，同比下降26.88%。 ...

证券代码：600422 证券简称：昆药集团 公告编号：2025-050号 昆药集团股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年10月10日 (二)股东大会召开的地点：云南省昆明市国家高新技术开发区科医路166号昆药集团股份有限公司管理 中心 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议的召集、召开程序符合《中华人民共和国公司法》《上市公司股东会规则》（下称"《股东会 规则》"）及《昆药集团股份有限公司公司章程》（下称"《公司章程》"）的有关规定，本次股东大会 会议由董事长吴文多先生主持。 二、议案审议情况 (一)非累积投票议案 1、议案名称：关于聘请公司2025年度审计机构的议案 审议结果：通过 表决情况： (五)公司董事、监事和董事会秘书的出席情况 1、公 ...

北京德恒（昆明）律师事务所 关于昆药集团股份有限公司 2025 年第四次临时股东会的 2025 年第四次临时股东会的 法 律 意 见 昆药集团股份有限公司： 云南省昆明市西山区西园路 126 号"融城优郡"B5 幢 3、4 层 电话（传真）：0871-63172192 邮编: 650032 法律意见 北京德恒（昆明）律师事务所 关于昆药集团股份有限公司 2025 年第四次临时股东会的法律意见 北京德恒（昆明）律师事务所 Beijing DeHeng Law Offices (KunMing) 北京德恒（昆明）律师事务所 关于昆药集团股份有限公司 决权股份数为316,628,271股，占贵公司有表决权的股份总数的41.8280%。其中， 出席本次股东会现场会议的股东及股东代理人共4名，代表有表决权股份数为 212,386,016股，占贵公司有表决权的股份总数的28.0572%；出席网络投票表决的 股东共944名，代表有表决权股份数为104,242,255股，占贵公司有表决权的股份 总数的13.7709%；出席本次股东会的中小股东共946名，代表有表决权股份数为 44,333,925股，占贵公司有表决权的股份总数 ...

证券代码：600422 证券简称：昆药集团 公告编号：2025-050 号 昆药集团股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 10 月 10 日 (二)股东大会召开的地点：云南省昆明市国家高新技术开发区科医路 166 号昆药 集团股份有限公司管理中心 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 948 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 316,628,271 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总 | 41.8280 | | 数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | ...

Core Points - The 2025 Hong Kong International Traditional Chinese Medicine Conference opened on September 25, focusing on the theme "Revitalizing Traditional Medicine for the Benefit of Human Health" [1] - The conference attracted over 130 well-known enterprises and institutions from countries involved in the Belt and Road Initiative, showcasing the global interest in traditional Chinese medicine [1] Company Highlights - Five listed Chinese medicine companies, including China Resources Sanjiu, Tianshi, and Kunming Pharmaceutical Group, collaborated with Zijing Culture to launch the "Traditional Chinese Medicine Culture Co-Link Initiative" [1] - The companies presented the "Traditional Chinese Medicine Culture" blue book and shared achievements in industry chain construction, highlighting their commitment to the development of traditional Chinese medicine [1] Industry Insights - The conference provided a platform for the Chinese medicine industry to gain domestic and international recognition for its achievements in industry chain construction [1] - The initiative aims to promote traditional Chinese medicine from being a "Chinese treasure" to a "global shared resource," contributing Chinese wisdom and solutions to global health [1]

昆药集团股份有限公司 KPC Pharmaceuticals, Inc. 2025 年第四次临时股东大会 一、本次股东大会由公司董事会办公室具体负责大会的组织工作。 二、董事会以维护股东的合法权益，确保大会正常秩序和议事效率为原则，认真 履行法定职责。 会 议 资 料 股票简称：昆药集团 股票代码：600422 2025 年 10 月 2025 年第四次临时股东大会会议资料 会 议 须 知 为适应上市公司规范运作，提高股东大会议事效率，保障股东合法权益，确保大 会程序合法性，根据《中华人民共和国公司法》《中华人民共和国证券法》《公司章 程》以及《公司股东大会议事规则》等精神，特制定如下大会须知，望出席昆药集团 股份有限公司（以下简称"昆药集团"或"公司"）股东大会的全体人员严格遵守： 三、出席本次股东大会的股东，依法享有发言权、表决权等各项权利。 四、会议期间请保持会场纪律、严肃对待每一项议题，会议期间全过程录音。 五、股东及股东代表参加本次股东大会，应当认真履行法定义务，不得侵犯其他 股东的权益，不得扰乱大会的正常程序和会议秩序。 六、会议议题全部说明完毕后统一审议、统一表决；股东大会采取现场投票和网 络投 ...

Core Viewpoint - The announcement details the progress of guarantees provided by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. for its subsidiary Kunming Pharmaceutical Group, specifically for its wholly-owned subsidiaries [1][3][7] Summary by Sections Guarantee Overview - The total guarantee amount for the subsidiaries is set at 14 million RMB, with a cumulative guarantee balance of 39.8 million RMB already provided [1][2] - The guarantee is within the previously estimated limits and does not involve any counter-guarantees [2] Guarantee Progress - The guarantees are aimed at supporting the operational and business development needs of Kunming Pharmaceutical Group's subsidiaries [4] - The guarantee plan was approved during the board meeting and the annual shareholders' meeting [3] Company Information - The guaranteed companies, Xishuangbanna Dai Medicine and Dali Huirui Pharmaceutical, have a good credit status and are not listed as dishonest executors [5] Guarantee Agreement Details - The guarantee period lasts for three years from the date of the agreement [6] - Other shareholders of Dali Huirui have signed a maximum guarantee contract, with individual shareholders assuming joint guarantee responsibilities [6] Necessity and Reasonableness of Guarantee - The guarantees are deemed necessary to meet the production and operational needs of Kunming Pharmaceutical Group for 2025, enhancing financing efficiency and reducing costs [6] - The company maintains oversight of the financial status and cash flow of the guaranteed subsidiaries, ensuring manageable risk [6] Cumulative Guarantee Amounts - As of the announcement date, the total external guarantee balance for Kunming Pharmaceutical Group and its subsidiaries is 122.2 million RMB, representing 2.33% of the latest audited net assets [6] - The total guarantee limit for 2025 for Kunming Pharmaceutical Group and Tian Shi Li Pharmaceutical Group is 1.35615 billion RMB, accounting for 6.81% of the latest audited net assets [7]

证券代码：600422 证券简称：昆药集团 公告编号：2025-049 号 昆药集团股份有限公司关于对外担保的进展公告 重要内容提示： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 担保对象及基本情况 | | 被担保人名称 | | 昆药商业西双版纳傣医药经营有限公司（以下简 | | --- | --- | --- | --- | | | | 称"版纳傣医药"） | | | | 本次担保金额 | 500 万元 | | | 担保对象一 | 实际为其提供的担保余额 | 万元 500 | | | | 是否在前期预计额度内 | 是 □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 否 | 不适用：_________ | | 担保对象二 | 被担保人名称 | | 大理辉睿药业有限公司（以下简称"大理辉睿"） | | | 本次担保金额 | 万元 900 | | | | 实际为其提供的担保余额 | 3,480 万元 | | | | 是否在前期预计额度内 | □否 是 | □不适用：_________ ...

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The pricing power of innovative drugs is improving, reflecting the global competitiveness of Chinese pharmaceutical companies [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions due to continued domestic substitution and accelerated overseas business progress [2]. - The neurosurgery and neurointervention fields are experiencing stable growth post-collection, with new products being launched [2]. - The high-value consumables market is expected to benefit from ongoing domestic replacement and the introduction of new products [2]. Group 3: Medical Devices - The medical device sector is seeing a recovery in bidding prices, with ongoing high-speed growth in bidding data this year [2]. - Companies are entering a phase of inventory reduction, with performance expected to improve in the second half of the year [2]. - The low-value consumables sector is experiencing product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is concentrating on central state-owned enterprises, gradually clearing the competitive landscape [2]. - The demand side is expected to see continuous upgrades to new products, with industry sentiment gradually improving [2]. Group 5: API (Active Pharmaceutical Ingredients) - The API sector is benefiting from the end of a capital expenditure peak, with three growth logic points driving upward trends: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies in the API sector are expected to see explosive growth in revenue and profits [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is witnessing a recovery in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs and ongoing observation of collection progress [2]. - The retail pharmacy sector is influenced by the pace of supply-side clearing and business model upgrades, with expectations of increased store closures in the second half of 2025 [2]. Group 8: Research and Development Services - The domestic innovative drug business development is heating up, likely driving downstream demand recovery [2]. - The overseas market presents significant growth opportunities for domestic companies, leveraging cost-effectiveness and service differentiation [2].

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The industry is positioned for a "Davis double" effect, where both performance and valuation are expected to improve [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions, while domestic replacements continue to grow, and overseas business progresses rapidly [2]. - The neurosurgery and neurointervention fields are stabilizing after centralized procurement, with new products expected to contribute to growth [2]. Group 3: Medical Devices - The medical device sector is experiencing a high-speed growth in bidding data, with companies entering a destocking phase, which is expected to improve performance in the second half of the year [2]. - The low-value consumables sector is seeing continuous product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is increasingly concentrated among state-owned enterprises, leading to a clearer competitive landscape [2]. - The demand side is expected to upgrade towards new products, gradually improving the industry's overall health [2]. Group 5: API (Active Pharmaceutical Ingredients) - The industry is at an upward turning point due to the end of a capital expenditure peak, combined with three growth drivers: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies are expected to see explosive growth in revenue and profits in the medium term [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is seeing a revival in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs, while the retail pharmacy sector is influenced by supply-side adjustments and business model upgrades [2]. - The performance of offline pharmacies is expected to improve in the second half of 2025, with leading chains like YaoXingTang making progress in store upgrades [2]. Group 8: Research Reports - A series of in-depth research reports on various companies and sectors within the pharmaceutical and medical device industries have been published, highlighting their growth potential and market positioning [3][4].